Ginkgo Bioworks Holdings, Inc. (DNA): Total Assets
$1.12B
As of 2025-12-31
$990.05M
As of 2026-06-30
-23.9%
3-year compound annual growth
+10.6%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.12B | -18.7% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $1.38B | -17.3% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $1.67B | -34.4% | 2025-02-25, Balance as of period end |
| 2022-12-31 | $2.54B | +22.6% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $2.07B | +206.7% | 2023-03-13, Balance as of period end |
| 2020-12-31 | $675.15M | n/a | 2022-03-29, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $1.12B | -18.7% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $453.03M | -2.8% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $245.96M | -13.0% |
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | $1.48B | +34.2% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $448.66M | +2.3% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $186.08M | +11.8% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $20.23M | -81.5% |
| Agenus Inc (AGEN) | 2025-12-31 | $226.80M | +0.2% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $501.90M | +31.1% |
Compare DNA, RGNX, ADAPY, BEAM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗